Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8608379 | 0.90 | MAOA (0.33) | MAOAMAOB | |
| SCHEMBL7776295 | 0.68 | — | — | |
| SCHEMBL1078392 | 0.68 | — | — | |
| SCHEMBL3293899 | 0.67 | MAPT (0.42) | — | |
| SCHEMBL11563490 | 0.66 | — | — | |
| SCHEMBL14123503 | 0.65 | — | — | |
| SCHEMBL27526976 | 0.65 | MAPT (0.30) | — | |
| SCHEMBL2852291 | 0.64 | CHRNB2 (0.30) | — | |
| SCHEMBL18551254 | 0.64 | — | — | |
| SCHEMBL745644 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| EP-1458686-A1 | BENZOCYCLODECANE DERIVATIVES WITH ANTITUMOR ACTIVITY | Pharmacia Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055861-A1 | BENZOCYCLODECANE DERIVATIVES WITH ANTITUMOR ACTIVITY | PHARMACIA ITALIA SPA (IT) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 | MAOA 4759/4885MAOB 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.